Rigel Pharmaceuticals News and Activities
Presence
Rigel Pharmaceuticals develops and sells prescription medicines for blood, immune, and rare diseases. Its products and research programs serve patients, healthcare providers, and pharmaceutical partners.
Rigel Pharmaceuticals products and services overview:
- Prescription medicines
- Rare disease treatments
- Immune disorder therapies
- Blood disease treatments
- Drug discovery
Revenue: ~$170 million
Employees: 170
Headquarters: South San Francisco, United States (USA)
Rigel Pharmaceuticals is one of the...
Rigel Pharmaceuticals is a company listed under the stock ticker RIGL (US).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Rigel Pharmaceuticals
- Raul Rodriguez, President and Chief Executive Officer
- Walter Moos, Director
- Gregg LaPointe, Director
Popular executive movements at Rigel Pharmaceuticals
- Michael Miller has joined the company as Director (posted on February 4 2026).
Create your alert
to follow the executive moves at Rigel Pharmaceuticals.
Pharmaceuticals
Rigel Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Rigel Pharmaceuticals
- Rigel to Present at the Jefferies Global Healthcare Conference
- Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
- Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
- Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
- Rigel Reports First Quarter 2026 Financial Results
- Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
- Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
- Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
- Rigel Appoints Michael P. Miller to the Board of Directors
- View more press releases Close
Social media about Rigel Pharmaceuticals
- Rigel Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Rigel Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
